BioLineRx’s (BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in…
Archived Articles
Legendary Icahn Still Slugging Away With Enzon Pharma
Carl C. Icahn has been the principal beneficial shareholder of Icahn Enterprises L.P. (NYSE: IEP) and has served as Chairman of the board, a director, and an owner of the company’s general partner since 1990. Mr. Icahn heads the investment…
Tuesday’s Small Cap Biopharma Investment And Catalyst Trade List
At Stockmatusow.com, my team of traders and investors scan the biotech sector daily, looking for stocks we believe provide excellent trading and investment opportunities. We factor in potential price moving catalyst events along with chart technicals and current news events,…
EDAP: An Undervalued Company With An Alternative Treatment For Prostate Cancer
In doing some fresh scans for 2013, I found a company that has a very small market cap of only $38 million but competes in the very large market of prostate cancer. EDAP TMS SA (EDAP) looks like a very…
BioTech wrap up for December 21st $ALXA $FOLD
$ALXA and $FOLD Commentary, Merry Christmas and a happy new year to everyone!
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Ziopharma (ZIOP) Trading Thesis
Ziopharm Oncology (ZIOP) is a cancer biotech with pivotal P3 results expected during Q1 2013 for lead pipeline product, ZYMAFOS, in addition to several other compounds in early-mid stages of clinical development and another ongoing P3 trial for ZYMAFOS that…
Osiris Therapeutics (OSIR) Catalyst Trade Thesis
Osiris Therapeutics (OSIR) Osiris expects to have data in hand (final data collection date for primary outcome measure) by the end of this year for the Phase III evaluation of Prochymal (remestemcel-L), which is an adult human stem cells treatment…
Trade alert: I bought bullish chart, target = $10.75
Trade alert: $OSIR P3 data by end of year, bullish chart, target = $10.75 RSI trending: short term cup, downside resistance, decent volume could move near $11. DISCLAIMER: This post is intended for informational and entertainment use…
